{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:22:47Z","timestamp":1788445367364,"version":"build-2803163510"},"reference-count":251,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimie"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.biochi.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T09:11:30Z","timestamp":1720948290000},"page":"135-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PA","title":["CD38\/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-6922","authenticated-orcid":false,"given":"Brigitte","family":"Bauvois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Nguyen-Khac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Merle-B\u00e9ral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos A.","family":"Susin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biochi.2024.07.006_bib1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib2","doi-asserted-by":"crossref","DOI":"10.13055\/ojhmt_3_S1_03.120221","article-title":"Cell trafficking in chronic lymphocytic leukemia","volume":"3","author":"Davids","year":"2012","journal-title":"Open J. Hematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246026","article-title":"Current status of novel agents for the treatment of B cell malignancies: what's coming next?","volume":"14","author":"Tannoury","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib4","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.biochi.2024.07.006_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071538","article-title":"Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity","volume":"13","author":"Wright","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biochi.2024.07.006_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination","volume":"15","author":"Lew","year":"2022","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114009","article-title":"Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib","volume":"229","author":"Ran","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biochi.2024.07.006_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.2022.281266","article-title":"PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?","volume":"108","author":"Sk\u00e5nland","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.biochi.2024.07.006_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2402339","article-title":"CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia","volume":"16","author":"D\u00fcrig","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1615\/CritRevImmunol.v35.i5.50","article-title":"Role of CD38 expression in diagnosis and pathogenesis of chronic lymphocytic leukemia and its potential as therapeutic target","volume":"35","author":"Burgler","year":"2015","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib12","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-18-3412","article-title":"Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia","volume":"25","author":"Manna","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-15-2095","article-title":"The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia","volume":"23","author":"Matas-C\u00e9spedes","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174169","article-title":"Targeting CD38 in neoplasms and non-cancer diseases","volume":"14","author":"Szlasa","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2019.00760","article-title":"CD38 in adenosinergic pathways and metabolic Re-programming in human multiple myeloma cells: in-tandem insights from basic science to therapy","volume":"10","author":"Horenstein","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.leu.2403667","article-title":"VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance","volume":"19","author":"Lee","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood-2007-08-109249","article-title":"Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B\/MMP-9 in chronic leukemic but not in normal B cells","volume":"112","author":"Redondo-Mu\u00f1oz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/leu.2011.369","article-title":"The CD49d\/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells","volume":"26","author":"Zucchetto","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fimmu.2019.00156","article-title":"Molecular players in hematologic tumor cell trafficking","volume":"10","author":"Redondo-Mu\u00f1oz","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41375-018-0303-x","article-title":"The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia","volume":"33","author":"Ten Hacken","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082124","article-title":"Relation of neutrophil gelatinase-associated lipocalin overexpression to the resistance to apoptosis of tumor B cells in chronic lymphocytic leukemia","volume":"12","author":"Bauvois","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/sj.bjc.6690167","article-title":"Constitutive expression of CD26\/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia","volume":"79","author":"Bauvois","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biochi.2024.07.006_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.leukres.2016.06.002","article-title":"The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia","volume":"47","author":"Matuszak","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib24","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood-2003-03-0989","article-title":"CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells","volume":"102","author":"Deaglio","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib25","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1182\/blood-2006-12-061812","article-title":"CD38\/CD19: a lipid raft-dependent signaling complex in human B cells","volume":"109","author":"Deaglio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib26","first-page":"338","article-title":"Prognostic markers in Chronic Lymphocytic Leukaemia - a flow cytometric analysis","volume":"36","author":"Haq","year":"2020","journal-title":"Pakistan J. Med. Sci."},{"key":"10.1016\/j.biochi.2024.07.006_bib27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.leu.2404087","article-title":"CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance","volume":"20","author":"Zucchetto","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bcmd.2015.05.010","article-title":"CD49d and CD26 are independent prognostic markers for disease progression in patients with chronic lymphocytic leukemia","volume":"55","author":"Ibrahem","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.biochi.2024.07.006_bib29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hon.888","article-title":"CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL","volume":"27","author":"Cro","year":"2009","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib30","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2010.36","article-title":"CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells","volume":"24","author":"Vaisitti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib31","first-page":"147","article-title":"Association of CD49d and CD44 in chronic lymphocytic leukemia patients and their effects on response to fludarabine, cyclophosphamide, and rituximab therapy","volume":"3","author":"Mahmoud","year":"2019","journal-title":"Journal of Current Medical Research and Practice"},{"key":"10.1016\/j.biochi.2024.07.006_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2141.2011.08725.x","article-title":"Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9","volume":"154","author":"Buggins","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2012.260","article-title":"CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells","volume":"27","author":"Vaisitti","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.leu.2404587","article-title":"Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin","volume":"21","author":"Pepper","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11092335","article-title":"The value of neutrophil gelatinase-associated lipocalin receptor as a novel partner of CD38 in chronic lymphocytic leukemia: from an adverse prognostic factor to a potential pharmacological target?","volume":"11","author":"Bauvois","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biochi.2024.07.006_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169159","article-title":"Spleen tyrosine kinase is involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia","volume":"11","author":"Benkisser-Petersen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2024.07.006_bib37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/leu.2014.207","article-title":"The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting","volume":"29","author":"Vaisitti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib38","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/bloodadvances.2017014506","article-title":"Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells","volume":"2","author":"Mele","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.biochi.2024.07.006_bib39","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood-2007-06-094029","article-title":"CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential","volume":"110","author":"Deaglio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.semcdb.2007.07.009","article-title":"Lipid rafts and B cell signaling","volume":"18","author":"Gupta","year":"2007","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib41","first-page":"1852","volume":"vol. 132","author":"Gentner","year":"2018"},{"key":"10.1016\/j.biochi.2024.07.006_bib42","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.3389\/fimmu.2018.02988","article-title":"Isotype specific assembly of B cell antigen receptors and synergism with chemokine receptor CXCR4","volume":"9","author":"Maity","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib43","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/eji.1830181124","article-title":"Cross-linking of membrane IgM on B CLL cells: dissociation between intracellular free Ca2+ mobilization and cell proliferation","volume":"18","author":"Hivroz","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib44","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V98.10.3050","article-title":"Survival of leukemic B cells promoted by engagement of the antigen receptor","volume":"98","author":"Bernal","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib45","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood-2002-02-0539","article-title":"Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta","volume":"100","author":"Ringshausen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib46","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","article-title":"The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells","volume":"111","author":"Longo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib47","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.346","article-title":"Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells","volume":"23","author":"Gobessi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib48","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1182\/blood-2013-10-534073","article-title":"Stimulation of the B-cell receptor activates the JAK2\/STAT3 signaling pathway in chronic lymphocytic leukemia cells","volume":"123","author":"Rozovski","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib49","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.2017.170571","article-title":"SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia","volume":"102","author":"Paiva","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.biochi.2024.07.006_bib50","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","article-title":"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406","volume":"114","author":"Quiroga","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib51","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib52","doi-asserted-by":"crossref","first-page":"35123","DOI":"10.18632\/oncotarget.26212","article-title":"CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase","volume":"9","author":"Montresor","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.biochi.2024.07.006_bib53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.4049\/jimmunol.1200615","article-title":"Divergence in CD19-mediated signaling unfolds intraclonal diversity in chronic lymphocytic leukemia, which correlates with disease progression","volume":"190","author":"Herishanu","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib54","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.leukres.2010.10.022","article-title":"CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL","volume":"35","author":"Majid","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib55","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1182\/blood-2004-10-4054","article-title":"CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium","volume":"105","author":"Till","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib56","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2019000019","article-title":"alpha4beta1 integrin associates with VEGFR2 in CLL cells and contributes to VEGF binding and intracellular signaling","volume":"3","author":"Gutierrez-Gonzalez","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.biochi.2024.07.006_bib57","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1158\/0008-5472.CAN-08-4173","article-title":"CD38\/CD31, the CCL3 and CCL4 chemokines, and CD49d\/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival","volume":"69","author":"Zucchetto","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.leu.2401275","article-title":"Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax","volume":"13","author":"de la Fuente","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib59","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1189\/jlb.71.3.495","article-title":"Engagement of alpha4beta1 integrin by fibronectin induces in\u00a0vitro resistance of B chronic lymphocytic leukemia cells to fludarabine","volume":"71","author":"de la Fuente","year":"2002","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2009.12.044","article-title":"Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain","volume":"17","author":"Redondo-Munoz","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biochi.2024.07.006_bib61","doi-asserted-by":"crossref","first-page":"27601","DOI":"10.1074\/jbc.M112.354670","article-title":"A\u00a017-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds alpha4beta1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells","volume":"287","author":"Ugarte-Berzal","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2024.07.006_bib62","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1182\/blood-2006-03-007294","article-title":"MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration","volume":"108","author":"Redondo-Mu\u00f1oz","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib63","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3109\/10428194.2011.569962","article-title":"Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1","volume":"52","author":"Herishanu","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biochi.2024.07.006_bib64","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1182\/blood-2012-11-466250","article-title":"CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia","volume":"121","author":"Fedorchenko","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib65","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood-2017-08-802462","article-title":"Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia","volume":"131","author":"Gutjahr","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fimmu.2015.00177","article-title":"The role of CD44 in the pathophysiology of chronic lymphocytic leukemia","volume":"6","author":"Gutjahr","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib67","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib68","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2004-12-4918","article-title":"Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells","volume":"106","author":"Burger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib69","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2010-04-282400","article-title":"Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib","volume":"117","author":"Messmer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib70","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/sj.leu.2401602","article-title":"Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1)","volume":"13","author":"M\u00f6hle","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib71","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells","volume":"94","author":"Burger","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib72","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1182\/blood-2008-06-165068","article-title":"Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach","volume":"113","author":"Niedermeier","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib73","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood-2003-08-2763","article-title":"VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia","volume":"104","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib74","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1158\/1078-0432.CCR-10-0232","article-title":"The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in\u00a0vitro and in\u00a0vivo","volume":"16","author":"Paesler","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib75","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2009-08-239426","article-title":"VEGF\/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration","volume":"115","author":"Ugarte-Berzal","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010052","article-title":"The good, the bad and the unknown of CD38 in the metabolic microenvironment and immune cell functionality of solid tumors","volume":"9","author":"Konen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.biochi.2024.07.006_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25204844","article-title":"The circular life of human CD38: from basic science to clinics and back","volume":"25","author":"Horenstein","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biochi.2024.07.006_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib79","article-title":"CD38 and regulation of the immune response cells in cancer","volume":"2021","author":"Dwivedi","year":"2021","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.biochi.2024.07.006_bib80","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V98.1.181","article-title":"CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia","volume":"98","author":"Ibrahim","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib82","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","article-title":"CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease","volume":"99","author":"Hamblin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib83","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","article-title":"The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression","volume":"101","author":"Ghia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.0007-1048.2001.3205.x","article-title":"CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia","volume":"116","author":"Chevallier","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib85","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejmhg.2012.03.007","article-title":"Prognostic significance of del 17p, ZAP70 and CD38 as independent indicators for B-CLL: correlation to response to treatment and disease outcome","volume":"13","author":"El-Kinawy","year":"2012","journal-title":"The Egyptian Journal of Medical Human Genetics"},{"key":"10.1016\/j.biochi.2024.07.006_bib86","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tcb.2020.11.004","article-title":"Dynamic plasma membrane organization: a complex symphony","volume":"31","author":"van Deventer","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061396","article-title":"Mechanisms of B Cell receptor activation and responses to B cell receptor inhibitors in B cell malignancies","volume":"12","author":"Efremov","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib88","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1053\/j.seminhematol.2014.05.003","article-title":"The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia","volume":"51","author":"Stevenson","year":"2014","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib89","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies","volume":"119","author":"Agathangelidis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib90","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/S2352-3026(14)00005-2","article-title":"Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study","volume":"1","author":"Baliakas","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.biochi.2024.07.006_bib91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib92","first-page":"319","article-title":"A\u00a0further characterization of B-CLL lymphocytes: phenotypic and functional studies","volume":"32","author":"Merle-B\u00e9ral","year":"1990","journal-title":"Nouv. Rev. Fr. Hematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib93","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/1097-0142(19901015)66:8<1738::AID-CNCR2820660816>3.0.CO;2-L","article-title":"Immunophenotypes in \"classical\" B-cell chronic lymphocytic leukemia. Correlation with normal cellular counterpart and clinical findings","volume":"66","author":"Baldini","year":"1990","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.biochi.2024.07.006_bib94","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10428199309064278","article-title":"Chronic lymphocytic leukemia--correlation of response and survival","volume":"11","author":"Keating","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biochi.2024.07.006_bib95","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10654-005-3777-6","article-title":"A\u00a0population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models","volume":"20","author":"Cailliod","year":"2005","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.biochi.2024.07.006_bib96","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.1007\/s13277-015-3741-3","article-title":"High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders","volume":"36","author":"Caivano","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.biochi.2024.07.006_bib97","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12964-023-01264-4","article-title":"Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.biochi.2024.07.006_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143512","article-title":"VLA-4 induces chemoresistance of T cell acute lymphoblastic leukemia cells via PYK2-mediated drug efflux","volume":"13","author":"Berrazouane","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215160","article-title":"The role of the microenvironment and cell adhesion molecules in chronic lymphocytic leukemia","volume":"15","author":"Cerreto","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib100","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1186\/s12967-023-04696-1","article-title":"The characteristics and the multiple functions of integrin \u03b21 in human cancers","volume":"21","author":"Sun","year":"2023","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib101","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.3390\/ijms21062206","article-title":"VLA-4 expression and activation in B cell malignancies: functional and clinical aspects","volume":"21","author":"H\u00e4rzschel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biochi.2024.07.006_bib102","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/blood-2013-06-507335","article-title":"CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism","volume":"122","author":"Zucchetto","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib103","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/leu.2017.296","article-title":"NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-\u03baB pathways","volume":"32","author":"Benedetti","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib104","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2007-05-092486","article-title":"Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia","volume":"111","author":"Gattei","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib105","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3324\/haematol.13103","article-title":"CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia","volume":"93","author":"Rossi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.biochi.2024.07.006_bib106","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2007.06965.x","article-title":"CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential","volume":"140","author":"Shanafelt","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib107","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V99.8.2977","article-title":"The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes","volume":"99","author":"Till","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib108","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/bjh.14647","article-title":"CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia","volume":"178","author":"Strati","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib109","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1182\/blood.2019003179","article-title":"CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression","volume":"135","author":"Tissino","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20171288","article-title":"Functional and clinical relevance of VLA-4 (CD49d\/CD29) in ibrutinib-treated chronic lymphocytic leukemia","volume":"215","author":"Tissino","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib111","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","article-title":"CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy","volume":"29","author":"Alsadhan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib112","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0301-472X(99)00023-5","article-title":"CD44 isoforms in normal and leukemic hematopoiesis","volume":"27","author":"Ghaffari","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib113","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/1535370213480714","article-title":"CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches","volume":"238","author":"Williams","year":"2013","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205041","article-title":"CD44 intracellular domain: a long tale of a short tail","volume":"15","author":"Skandalis","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib115","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0923-2494(93)80061-3","article-title":"CD44 splice variants; expression on lymphocytes and in neoplasia","volume":"144","author":"Koopman","year":"1993","journal-title":"Res. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib116","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2017.00018","article-title":"CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells","volume":"5","author":"Senbanjo","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib117","first-page":"1088","article-title":"Functional and clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia cells","volume":"83","author":"Zarcone","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.biochi.2024.07.006_bib118","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.leukres.2004.01.016","article-title":"Elevated levels of soluble CD44 are associated with advanced disease and in\u00a0vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia","volume":"28","author":"Eisterer","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib119","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/0008-5472.CAN-12-2749","article-title":"CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility","volume":"73","author":"Girbl","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib120","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2011-01-333682","article-title":"ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1\/2 activation","volume":"118","author":"Calpe","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib121","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib122","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.1007\/s00432-022-04444-w","article-title":"CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment","volume":"149","author":"Bao","year":"2023","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib123","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/cbt.26607","article-title":"Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy","volume":"15","author":"Han","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biochi.2024.07.006_bib124","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4065\/79.3.318","article-title":"Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"79","author":"Ghobrial","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biochi.2024.07.006_bib125","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.3324\/haematol.2015.133470","article-title":"Combined CXCR3\/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors","volume":"101","author":"Ganghammer","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.biochi.2024.07.006_bib126","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55133\/eji.280312","article-title":"CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients","volume":"28","author":"El-Sherif","year":"2021","journal-title":"Egypt. J. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib127","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1182\/blood-2009-07-235184","article-title":"Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia","volume":"114","author":"Crowther-Swanepoel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib128","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib129","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0065-230X(08)60716-2","article-title":"Role of VEGF-flt receptor system in normal and tumor angiogenesis","volume":"67","author":"Shibuya","year":"1995","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1359-6101(96)00027-5","article-title":"Vascular endothelial growth factor and its receptors","volume":"7","author":"Klagsbrun","year":"1996","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biochi.2024.07.006_bib131","article-title":"Molecular bases of VEGFR-2-mediated physiological function and pathological role","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib132","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0145-2126(00)00161-2","article-title":"Angiogenesis and leukemia","volume":"25","author":"Keyhani","year":"2001","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib133","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.seminoncol.2006.01.008","article-title":"The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia","volume":"33","author":"Shanafelt","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib134","first-page":"795","article-title":"High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia","volume":"7","author":"Ferrajoli","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib135","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1074\/jbc.M115.685644","article-title":"Biochemical and structural characterization of the interaction between the siderocalin NGAL\/LCN2 (neutrophil gelatinase-associated lipocalin\/lipocalin 2) and the N-terminal domain of its endocytic receptor SLC22A17","volume":"291","author":"Cabedo Martinez","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2024.07.006_bib136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071586","article-title":"Expression and function of the lipocalin-2 (24p3\/NGAL) receptor in rodent and human intestinal epithelia","volume":"8","author":"Langelueddecke","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2024.07.006_bib137","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/jcp.2010.083907","article-title":"Neutrophil gelatinase-associated lipocalin and its receptor: independent prognostic factors of oesophageal squamous cell carcinoma","volume":"64","author":"Du","year":"2011","journal-title":"J.\u00a0Clin. Pathol."},{"key":"10.1016\/j.biochi.2024.07.006_bib138","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11060-010-0486-0","article-title":"NGAL and NGALR are frequently overexpressed in human gliomas and are associated with clinical prognosis","volume":"104","author":"Liu","year":"2011","journal-title":"J.\u00a0Neuro Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib139","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3892\/ol_00000019","article-title":"Overexpression of neutrophil gelatinase-associated lipocalin and its receptor in colorectal carcinoma: significant correlation with cell differentiation and tumour invasion","volume":"1","author":"Lv","year":"2010","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biochi.2024.07.006_bib140","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/j.canep.2012.05.012","article-title":"NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification","volume":"36","author":"Zhang","year":"2012","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.biochi.2024.07.006_bib141","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.gene.2018.08.060","article-title":"The expression analysis of NGAL and NGALR in clear cell renal cell carcinoma","volume":"676","author":"Liu","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.biochi.2024.07.006_bib142","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2005.10.027","article-title":"A\u00a0cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake","volume":"123","author":"Devireddy","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.biochi.2024.07.006_bib143","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1189\/jlb.70.1.11","article-title":"Transmembrane proteases in focus: diversity and redundancy?","volume":"70","author":"Bauvois","year":"2001","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib144","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2741\/4671","article-title":"A\u00a0novel role for CD26\/dipeptidyl peptidase IV as a therapeutic target","volume":"23","author":"Ohnuma","year":"2018","journal-title":"Front. Biosci."},{"key":"10.1016\/j.biochi.2024.07.006_bib145","article-title":"Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia","volume":"17","author":"Ebian","year":"2022","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.biochi.2024.07.006_bib146","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0609.2009.01273.x","article-title":"Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia","volume":"83","author":"Molica","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib147","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.onc.1203292","article-title":"Regulation of CD26\/DPPIV gene expression by interferons and retinoic acid in tumor B cells","volume":"19","author":"Bauvois","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.biochi.2024.07.006_bib148","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4161\/cbt.10.2.12168","article-title":"Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia","volume":"10","author":"Sulda","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biochi.2024.07.006_bib149","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cyto.b.20593","article-title":"Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation","volume":"80","author":"Degheidy","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.biochi.2024.07.006_bib150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.beha.2016.08.007","article-title":"The chronic lymphocytic leukemia microenvironment: beyond the B-cell receptor","volume":"29","author":"Choi","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.biochi.2024.07.006_bib151","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib152","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.bcp.2010.07.039","article-title":"Inflammation and survival pathways: chronic lymphocytic leukemia as a model system","volume":"80","author":"Chen","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biochi.2024.07.006_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2021.102514","article-title":"The calcium signaling enzyme CD38 - a paradigm for membrane topology defining distinct protein functions","volume":"101","author":"Lee","year":"2022","journal-title":"Cell Calcium"},{"key":"10.1016\/j.biochi.2024.07.006_bib154","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3324\/haematol.2013.098384","article-title":"The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy","volume":"99","author":"Packham","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.biochi.2024.07.006_bib155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biochi.2024.07.006_bib156","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1182\/blood-2007-11-125278","article-title":"The NF-kappaB subunit Rel A is associated with in\u00a0vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target","volume":"111","author":"Hewamana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib157","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2007-09-111344","article-title":"Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy","volume":"112","author":"Muzio","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib158","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2006-03-012021","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII","volume":"109","author":"Abrams","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib159","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","article-title":"Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia","volume":"69","author":"Buchner","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib161","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI200522094","article-title":"Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis","volume":"115","author":"Contri","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.biochi.2024.07.006_bib162","first-page":"55","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies","volume":"14","author":"Koehrer","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib163","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"D\u00fchren-von Minden","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.biochi.2024.07.006_bib164","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15746","article-title":"Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia","volume":"8","author":"Minici","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biochi.2024.07.006_bib165","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.celrep.2019.06.069","article-title":"Constitutive activation of the B cell receptor underlies dysfunctional signaling in chronic lymphocytic leukemia","volume":"28","author":"Ziegler","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.biochi.2024.07.006_bib166","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.biochi.2024.07.006_bib167","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib168","doi-asserted-by":"crossref","DOI":"10.3390\/genes14122182","article-title":"Resisting the resistance: navigating BTK mutations in chronic lymphocytic leukemia (CLL)","volume":"14","author":"Chirino","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.biochi.2024.07.006_bib169","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1387\/ijdb.150204om","article-title":"Calcium signaling and cell fate: how can Ca2+ signals contribute to wrong decisions for Chronic Lymphocytic Leukemic B lymphocyte outcome?","volume":"59","author":"Debant","year":"2015","journal-title":"Int. J. Dev. Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib170","article-title":"The antigen receptor as a driver of B-cell lymphoma development and evolution","volume":"2","author":"Sepulveda","year":"2017","journal-title":"Intech"},{"key":"10.1016\/j.biochi.2024.07.006_bib171","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1172\/JCI24387","article-title":"Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity","volume":"115","author":"Herv\u00e9","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.biochi.2024.07.006_bib172","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood-2007-11-125450","article-title":"A\u00a0new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies","volume":"111","author":"Lanemo Myhrinder","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib173","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1182\/blood-2011-08-374058","article-title":"Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen","volume":"119","author":"Steininger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib174","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20121801","article-title":"A\u00a0mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi","volume":"210","author":"Hoogeboom","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib175","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood-2012-08-447904","article-title":"Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells","volume":"121","author":"Zwick","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib176","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.4049\/jimmunol.1600915","article-title":"Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia","volume":"197","author":"Ten Hacken","year":"2016","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib177","first-page":"29","article-title":"New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression","volume":"1825","author":"Bauvois","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biochi.2024.07.006_bib178","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023758","article-title":"Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells","volume":"6","author":"Brachtl","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2024.07.006_bib179","first-page":"80","article-title":"The role of CD49d Iin chronic lymphocytic leukemia: microenvironmental interactions and clinical relevance","volume":"1","author":"Dal Bo","year":"2014","journal-title":"European Medical Journal Hematol"},{"key":"10.1016\/j.biochi.2024.07.006_bib180","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3324\/haematol.2022.281999","article-title":"Sialylation regulates migration in chronic lymphocytic leukemia","volume":"108","author":"Natoni","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.biochi.2024.07.006_bib181","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3389\/fonc.2018.00645","article-title":"BCL2-Family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker","volume":"8","author":"Tessoulin","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib182","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083830","article-title":"The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells","volume":"8","author":"Fiorcari","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2024.07.006_bib183","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib184","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fimmu.2015.00154","article-title":"CD44 acts as a signaling platform controlling tumor progression and metastasis","volume":"6","author":"Orian-Rousseau","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1189\/jlb.3CE0314-143R","article-title":"Editorial: pro-matrix metalloproteinase-9 in tumor B lymphocytes: balancing migration and homing","volume":"96","author":"Bauvois","year":"2014","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib186","article-title":"CAR-T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib187","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.leu.2403282","article-title":"CD38 expression on B-cell chronic lymphocytic leukemic cells is strongly correlated with vascular endothelial growth factor expression","volume":"18","author":"McCabe","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib188","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.leu.2403837","article-title":"VEGF-induced survival of chronic lymphocytic leukemia is independent of Bcl-2 phosphorylation","volume":"19","author":"Wang","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib189","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2119\/molmed.2010.00210","article-title":"Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells","volume":"17","author":"Gehrke","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib190","doi-asserted-by":"crossref","first-page":"E336","DOI":"10.3390\/cancers10090336","article-title":"Revisiting neutrophil gelatinase-associated lipocalin (NGAL) in cancer: saint or sinner?","volume":"10","author":"Bauvois","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib191","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2016.09.007","article-title":"LYN kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia","volume":"30","author":"Nguyen","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biochi.2024.07.006_bib192","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.biochi.2024.07.006_bib193","article-title":"CD26\/Dipeptidyl peptidase IV and its multiple biological functions","volume":"13","author":"Pan","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.biochi.2024.07.006_bib194","first-page":"14","article-title":"Validating cell surface proteases as drug targets for cancer therapy: what do we know, and where do we go?","author":"Verhulst","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4757-9613-1_26","article-title":"Expression of dipeptidylpeptidase IV (DPP IV\/CD26) activity on human myeloid and B lineage cells, and cell growth suppression by the inhibition of DPP IV activity","volume":"421","author":"Micouin","year":"1997","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib196","doi-asserted-by":"crossref","first-page":"19532","DOI":"10.1074\/jbc.M004586200","article-title":"Comodulation of CXCR4 and CD26 in human lymphocytes","volume":"276","author":"Herrera","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biochi.2024.07.006_bib197","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2016-09-693598","article-title":"How I manage ibrutinib-refractory chronic lymphocytic leukemia","volume":"129","author":"Woyach","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib198","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10428194.2019.1660974","article-title":"Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease","volume":"61","author":"Blombery","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biochi.2024.07.006_bib199","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.689472","article-title":"Resistance mutations to BTK inhibitors originate from the NF-\u03baB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051328","article-title":"Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas","volume":"12","author":"George","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.591577","article-title":"Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies","volume":"10","author":"Ondrisova","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib202","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010087","article-title":"FDA-approved drugs for hematological malignancies-the last decade review","volume":"14","author":"Sochacka-\u0106wik\u0142a","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.biochi.2024.07.006_bib204","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.1182\/blood-2022-163096","article-title":"Combined treatment with ibrutinib and anti-CD38 monoclonal antibody daratumumab in relapsed\/refractory chronic lymphocytic leukemia with TP53 aberrations: results of the filo phase II study IDA53","volume":"140","author":"Aurran-Schleinitz","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib205","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib206","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/jco.2014.32.15_suppl.3028","article-title":"Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL","volume":"32","author":"Gladstone","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib207","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biochi.2024.07.006_bib208","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biochi.2024.07.006_bib209","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib210","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib211","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967956.37234.fb","article-title":"First in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed\/refractory (R\/R) B-cell malignancies","volume":"7","author":"Dickinson","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.biochi.2024.07.006_bib212","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood-2013-12-544569","article-title":"Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia","volume":"123","author":"Walsby","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib213","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1073\/pnas.1221841110","article-title":"Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biochi.2024.07.006_bib214","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib215","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1517\/13543776.2014.915942","article-title":"Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498","volume":"24","author":"D'Arena","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.biochi.2024.07.006_bib216","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.18632\/oncotarget.6465","article-title":"Ulocuplumab (BMS-936564\/MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biochi.2024.07.006_bib217","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib218","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In\u00a0vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin's lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biochi.2024.07.006_bib219","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fimmu.2020.00060","article-title":"Targeting natural killer cells for tumor immunotherapy","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib221","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \"Off-The-Shelf\" allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib222","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clml.2014.02.010","article-title":"Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma","volume":"14","author":"Hainsworth","year":"2014","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib223","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2017.62","article-title":"First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers","volume":"116","author":"Angevin","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biochi.2024.07.006_bib224","doi-asserted-by":"crossref","DOI":"10.3390\/cells12162059","article-title":"Development of a novel CD26-targeted chimeric antigen receptor T-cell therapy for CD26-expressing T-cell malignancies","volume":"12","author":"Kobayashi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biochi.2024.07.006_bib225","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2017.01936","article-title":"Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets","volume":"8","author":"Cuesta-Mateos","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib226","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib227","doi-asserted-by":"crossref","DOI":"10.3390\/cells12040531","article-title":"Chimeric antigen receptor T-cell therapy and hematopoiesis","volume":"12","author":"Reinhardt","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biochi.2024.07.006_bib228","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8070204","article-title":"Bi- and tri-specific T cell engager-armed oncolytic viruses: next-generation cancer immunotherapy","volume":"8","author":"Guo","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.biochi.2024.07.006_bib229","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/hematology.2020000110","article-title":"Bispecifics, trispecifics, and other novel immune treatments in myeloma","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.biochi.2024.07.006_bib230","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205053","article-title":"Editorial on \"cell therapy, bispecific antibodies and other immunotherapies against cancer\"","volume":"15","author":"Golubovskaya","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biochi.2024.07.006_bib231","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1060905","article-title":"A\u00a0tri-specific killer engager against mesothelin targets NK cells towards lung cancer","volume":"14","author":"Kennedy","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.07.006_bib232","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.biochi.2024.07.006_bib233","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.semcancer.2010.08.003","article-title":"CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells","volume":"20","author":"Deaglio","year":"2010","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biochi.2024.07.006_bib234","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2174\/15680266113136660210","article-title":"Multiple metamorphoses of CD38 from prognostic marker to disease modifier to therapeutic target in chronic lymphocytic leukemia","volume":"13","author":"Vaisitti","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.biochi.2024.07.006_bib235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.12703\/r\/10-39","article-title":"Tissue remodeling by invadosomes","volume":"10","author":"Cambi","year":"2021","journal-title":"Fac Rev"},{"key":"10.1016\/j.biochi.2024.07.006_bib236","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1126\/science.334.6059.1046-b","article-title":"Mysteries of the cell. Do lipid rafts exist?","volume":"334","author":"Leslie","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.biochi.2024.07.006_bib237","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/smll.201102183","article-title":"Direct evidence of lipid rafts by in situ atomic force microscopy","volume":"8","author":"Cai","year":"2012","journal-title":"Small"},{"key":"10.1016\/j.biochi.2024.07.006_bib238","first-page":"4","article-title":"Membrane domains and the \"lipid raft\" concept","volume":"20","author":"Sonnino","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biochi.2024.07.006_bib239","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s10238-023-01268-x","article-title":"Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.biochi.2024.07.006_bib240","first-page":"219","article-title":"Epigenetics, a key player of immunotherapy resistance","volume":"1","author":"Peixoto","year":"2018","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.biochi.2024.07.006_bib241","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/epi.09.10","article-title":"Large-scale analysis of DNA methylation in chronic lymphocytic leukemia","volume":"1","author":"Rahmatpanah","year":"2009","journal-title":"Epigenomics"},{"key":"10.1016\/j.biochi.2024.07.006_bib242","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ng.2443","article-title":"Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia","volume":"44","author":"Kulis","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biochi.2024.07.006_bib243","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ng.3488","article-title":"DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia","volume":"48","author":"Oakes","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biochi.2024.07.006_bib244","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ijc.31057","article-title":"NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib","volume":"142","author":"Wolf","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biochi.2024.07.006_bib245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13148-019-0783-1","article-title":"DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy","volume":"11","author":"Tsagiopoulou","year":"2019","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.biochi.2024.07.006_bib246","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1158\/0008-5472.CAN-10-1634","article-title":"Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription","volume":"70","author":"Buggins","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.biochi.2024.07.006_bib247","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8942042","article-title":"CD38\/cADPR signaling pathway in airway disease: regulatory mechanisms","volume":"2018","author":"Deshpande","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biochi.2024.07.006_bib248","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2014-12-575688","article-title":"Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia","volume":"126","author":"Somasundaram","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.07.006_bib249","first-page":"415","article-title":"Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors","volume":"36","author":"Katoh","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biochi.2024.07.006_bib250","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF01246674","article-title":"Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene","volume":"40","author":"Abbott","year":"1994","journal-title":"Immunogenetics"},{"issue":"Pt 3","key":"10.1016\/j.biochi.2024.07.006_bib251","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1042\/bj3110835","article-title":"Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter","volume":"311","author":"B\u00f6hm","year":"1995","journal-title":"Biochem. J."}],"container-title":["Biochimie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908424001652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908424001652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T16:37:42Z","timestamp":1733243862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300908424001652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":251,"alternative-id":["S0300908424001652"],"URL":"https:\/\/doi.org\/10.1016\/j.biochi.2024.07.006","relation":{},"ISSN":["0300-9084"],"issn-type":[{"value":"0300-9084","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD38\/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Biochimie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biochi.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. and Soci\u00e9t\u00e9 Fran\u00e7aise de Biochimie et Biologie Mol\u00e9culaire (SFBBM). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}